Biogen
225 Binney Street
Cambridge
Massachusetts
02142
United States
Tel: 781-464-2000
Website: https://www.biogen.com/
About Biogen
Biogen (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.
Founded in 1978, Biogen is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.
With about 4,800 employees worldwide, Biogen is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.
For product labeling, press releases and additional information about the company, please visit https://www.biogen.com/
FOLLOW BIOGEN: Tweets by Biogen
Biogen -- Caring Deeply, Changing Lives
1334 articles with Biogen
-
The current price for Spinraza is $750,000 for the first year and $375,000 for every year after for the life of the patient. It is approved for all forms of SMA, types 0 through 5.
-
The lynchpin to biotech and pharmaceutical drug development in the United States is arguably the greater Boston area, which includes the white hot square mile of talent and intellectual collaboration found in Kendall Square.
-
The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?
-
With Cowen & Company’s 39th Annual Health Care Conference going on in Boston this week, a lot of stories in the biopharma industry are coming out. Here are a few highlights.
-
The Hillerod subsidiary, Denmark Manufacturing ApS, has about 800 staffers, who are expected to continue working under Fujifilm.
-
With Boston and the surrounding area being one of the centers of the pharmaceutical world, it should come as no surprise that some of the top-selling medications are based in the Bay State.
-
For Biogen, the acquisition brings Nightstar’s lead asset, NSR-REP1, a treatment for treatment of choroideremia (CHM), a rare and degenerative, X-linked inherited retinal disorder that leads to blindness, into its pipeline.
-
BIOGEN ANNOUNCES AGREEMENT TO ACQUIRE NIGHTSTAR THERAPEUTICS TO ESTABLISH CLINICAL PIPELINE OF GENE THERAPY CANDIDATES IN OPHTHALMOLOGY
3/4/2019
Biogen (Nasdaq: BIIB) today announced that it has entered into an agreement to acquire Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders
-
Whenever a drug fails an Alzheimer’s clinical trial, analysts, investors and industry watchers immediately turn to look at Biogen. Will the company’s aducanumab be the one? Will it be the drug that will actually break the string of more than 150 drug failures?
-
Amgen and Allergan announced positive top-line results from a Phase I/Phase III trial of their biosimilar candidate, ABP 798, to Genentech and Biogen’s Rituxan (rituximab).
-
The U.S. Food and Drug Administration (FDA) approved South Korea’s Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar to Genentech’s Herceptin (trastuzumab).
-
The JP Morgan Healthcare Conference, being held from January 7 through 10 at the Westin St. Francis Hotel in San Francisco, is one of the premier, possible the premier, conferences for the biopharmaceutical industry.
-
With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.
-
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
-
Readers' Picks: Top 10 Stories of 2018
12/28/2018
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more. -
7 Biotech Trends to Look Out for in 2019
12/26/2018
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle. -
Using a calculation, ICER believes the Novartis gene therapy for Spinal Muscular Atrophy will be more cost effective than Biogen's Spinraza.
-
An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.
-
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
-
HitGen and Biogen enter a DNA-Encoded Library-Based Drug Discovery Research Collaboration
11/21/2018
HitGen will receive upfront payments, and be eligible for milestone payments.